Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1067-1084

  Elnakat, Hala ^a   Ratnam, Manohar ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Folate receptor; Gene regulation; Isoforms

Indexed keywords

DOXORUBICIN; ESTROGEN RECEPTOR; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID RECEPTOR ALPHA; FOLIC ACID RECEPTOR BETA; FOLIC ACID RECEPTOR GAMMA; LIPOSOME; RECEPTOR PROTEIN; RECEPTOR SUBTYPE; RETINOIC ACID; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; DRUG TARGETING; GENE CONTROL; GENE LOCATION; GENE TARGETING; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HYDROPHOBICITY; KNOCKOUT GENE; MOLECULAR MECHANICS; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; TISSUE SPECIFICITY;

EID: 1942503303     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.001     Document Type: Article

References (145)

1. Antony A.C. Folate receptors. Annu. Rev. Nutr. 16:1996;501-521.
2. Lacey S.W., Sanders J.M., Rothberg K.G., Anderson R.G., Kamen B.A. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. J. Clin. Invest. 84:1989;715-720.
3. Sadasivan E., Rothenberg S.P. The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA. J. Biol. Chem. 264:1989;5806-5811.
4. Elwood P.C. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J. Biol. Chem. 264:1989;14893-14901.
5. Ratnam M., Marquardt H., Duhring J.L., Freisheim J.H. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA. Biochemistry. 28:1989;8249-8254.
6. Shen F., Ross J.F., Wang X., Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 33:1994;1209-1215.
7. Shen F., Wu M., Ross J.F., Miller D., Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 34:1995;5660-5665.
8. Spiegelstein O., Eudy J.D., Finnell R.H. Identification of two putative novel folate receptor genes in humans and mouse. Gene. 258:2000;117-125.
9. Monaco H.L. Crystal structure of chicken riboflavin-binding protein. EMBO J. 16:1997;1475-1483.
10. Wistow G., Bernstein S.L., Wyatt M.K., Ray S., Behal A., Touchman J.W., Bouffard G., Smith D., Peterson K. Expressed sequence tag analysis of human retina for the NEIBank Project: retbindin, an abundant, novel retinal cDNA and alternative splicing of other retina-preferred gene transcripts. Mol. Vis. 8:2002;196-204.
11. Matherly L.H., Goldman D.I. Membrane transport of folates. Vitam. Horm. 66:2003;403-456.
12. Reddy J.A., Haneline L.S., Srour E.F., Antony A.C., Clapp D.W., Low P.S. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood. 93:1999;3940-3948.
13. Pan X.Q., Zheng X., Shi G., Wang H., Ratnam M., Lee R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood. 100:2002;594-602.
14. Selhub J., Nakamura S., Carone F.A. Renal folate absorption and the kidney folate binding protein: II. Microinfusion studies. Am. J. Physiol. 252:1987;F757-F760.
15. Selhub J., Emmanouel D., Stavropoulos T., Arnold R. Renal folate absorption and the kidney folate binding protein: I. Urinary clearance studies. Am. J. Physiol. 252:1987;F750-F756.
16. da Costa M., Rothenberg S.P., Sadasivan E., Regec A., Qian L. Folate deficiency reduces the GPI-anchored folate-binding protein in rat renal tubules. Am. J. Physiol. Cell. Physiol. 278:2000;C812-C821.
17. Gates S.B., Mendelsohn L.G., Shackelford K.A., Habeck L.L., Kursar J.D., Gossett L.S., Worzalla J.F., Shih C., Grindey G.B. Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression. Clin. Cancer Res. 2:1996;1135-1141.
18. Doucette M.M., Stevens V.L. Folate receptor function is regulated in response to different cellular growth rates in cultured mammalian cells. J. Nutr. 131:2001;2819-2825.
19. Henderson G.I., Perez T., Schenker S., Mackins J., Antony A.C. Maternal-to-fetal transfer of 5-methyltetrahydrofolate by the perfused human placental cotyledon: evidence for a concentrative role by placental folate receptors in fetal folate delivery. J. Lab. Clin. Med. 126:1995;184-203.
20. Piedrahita J.A., Oetama B., Bennett G.D., van Waes J., Kamen B.A., Richardson J., Lacey S.W., Anderson R.G., Finnell R.H. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat. Genet. 23:1999;228-232.
21. Wlodarczyk B., Spiegelstein O., Gelineau-van Waes J., Vorce R.L., Lu X., Le C.X., Finnell R.H. Arsenic-induced congenital malformations in genetically susceptible folate binding protein-2 knockout mice. Toxicol. Appl. Pharmacol. 177:2001;238-246.
22. Leamon C.P., Low P.S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today. 6:2001;44-51.
23. Drummond D.C., Hong K., Park J.W., Benz C.C., Kirpotin D.B. Liposome targeting to tumors using vitamin and growth factor receptors. Vitam. Horm. 60:2000;285-332.
24. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54:2002;675-693.
25. Ratnam M., Hao H., Zheng X., Wang H., Qi H., Lee R., Pan X. Receptor induction and targeted drug delivery: a new antileukaemia strategy. Expert Opin. Biol. Ther. 3:2003;563-574.
26. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41:2000;147-162.
27. Ward C.M. Folate-targeted non-viral DNA vectors for cancer gene therapy. Curr. Opin. Mol. Ther. 2:2000;182-187.
28. Atkinson S.F., Bettinger T., Seymour L.W., Behr J.P., Ward C.M. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J. Biol. Chem. 276:2001;27930-27935.
29. Ladino C.A., Chari R.V., Bourret L.A., Kedersha N.L., Goldmacher V.S. Folate-maytansinoids: target-selective drugs of low molecular weight. Int. J. Cancer. 73:1997;859-864.
30. Leamon C.P., Low P.S. Selective targeting of malignant cells with cytotoxin-folate conjugates. J. Drug Target. 2:1994;101-112.
31. Andersson H., Lindegren S., Back T., Jacobsson L., Leser G., Horvath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. Anticancer Res. 20:2000;459-462.
32. Konda S.D., Wang S., Brechbiel M., Wiener E.C. Biodistribution of a 153 Gd-folate dendrimer, generation=4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest. Radiol. 37:2002;199-204.
33. Leamon C.P., Parker M.A., Vlahov I.R., Xu L.C., Reddy J.A., Vetzel M., Douglas N. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug. Chem. 13:2002;1200-1210.
34. Mathias C.J., Wang S., Low P.S., Waters D.J., Green M.A. Receptor-mediated targeting of 67Ga-deferoxamine-folate to folate-receptor- positive human KB tumor xenografts. Nucl. Med. Biol. 26:1999;23-25.
35. Mathias C.J., Hubers D., Low P.S., Green M.A. Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug. Chem. 11:2000;253-257.
36. Visser G.W., Klok R.P., Gebbinck J.W., ter Linden T., van Dongen G.A., Molthoff C.F. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J. Nucl. Med. 42:2001;509-519.
37. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6:2000;1949-1957.
38. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
39. Pan X.Q., Wang H., Lee R.J. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res. 22:2002;1629-1633.
40. Qualls M.M., Thompson D.H. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: intracellular localization and synergistic phototoxicity. Int. J. Cancer. 93:2001;384-392.
41. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., Leamon C.P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9:2002;1542-1550.
42. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318-3322.
43. Zhou W., Yuan X., Wilson A., Yang L., Mokotoff M., Pitt B., Li S. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug. Chem. 13:2002;1220-1225.
44. Liu J., Kolar C., Lawson T.A., Gmeiner W.H. Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J. Org. Chem. 66:2001;5655-5663.
45. Lu J.Y., Lowe D.A., Kennedy M.D., Low P.S. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J. Drug Target. 7:1999;43-53.
46. Benns J.M., Maheshwari A., Furgeson D.Y., Mahato R.I., Kim S.W. Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J. Drug Target. 9:2001;123-139.
47. Dauty E., Remy J.S., Zuber G., Behr J.P. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug. Chem. 13:2002;831-839.
48. Quintana A., Raczka E., Piehler L., Lee I., Myc A., Majoros I., Patri A.K., Thomas T., Mule J., Baker J.R. Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19:2002;1310-1316.
49. Ward C.M., Pechar M., Oupicky D., Ulbrich K., Seymour L.W. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo. J. Gene Med. 4:2002;536-547.
50. Westerhof G.R., Schornagel J.H., Kathmann I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol. 48:1995;459-471.
51. Theti D.S., Bavetsias V., Skelton L.A., Titley J., Gibbs D., Jansen G., Jackman A.L. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res. 63:2003;3612-3618.
52. Bavetsias V., Marriott J.H., Melin C., Kimbell R., Matusiak Z.S., Boyle F.T., Jackman A.L. Design and synthesis of Cyclopenta[g]quinazoline-based antifolates as inhibitors of thymidylate synthase and potential antitumor agents(,). J. Med. Chem. 43:2000;1910-1926.
53. Lu Y., Low P.S. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J. Control. Release. 91:2003;17-29.
54. Mazzoni A., Mezzanzanica D., Jung G., Wolf H., Colnaghi M.I., Canevari S. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res. 56:1996;5443-5449.
55. Mezzanzanica D., Garrido M.A., Neblock D.S., Daddona P.E., Andrew S.M., Zurawski V.R. Jr., Segal D.M., Wunderlich J.R. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab′)2 antibody prolong host survival in a murine xenograft model. Cancer Res. 51:1991;5716-5721.
56. Canevari S., Stoter G., Arienti F., Bolis G., Colnaghi M.I., Di Re E.M., Eggermont A.M., Goey S.H., Gratama J.W., Lamers C.H. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. 87:1995;1463-1469.
57. Canevari S., Mezzanzanica D., Mazzoni A., Negri D.R., Ramakrishna V., Bolhuis R.L., Colnaghi M.I., Bolis G. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J. Hematother. 4:1995;423-427.
58. Canevari S., Mezzanzanica D., Mazzoni A., Negri D.R., Figini M., Ramakrishna V., Bolis G., Colnaghi M.I. Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunol. Immunother. 45:1997;187-189.
59. Luiten R.M., Warnaar S.O., Sanborn D., Lamers C.H., Bolhuis R.L., Litvinov S.V., Zurawski V.R. Jr., Coney L.R. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J. Immunother. 20:1997;496-504.
60. Melani C., Figini M., Nicosia D., Luison E., Ramakrishna V., Casorati G., Parmiani G., Eshhar Z., Canevari S., Colombo M.P. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58:1998;4146-4154.
61. Kim D.K., Lee T.V., Castilleja A., Anderson B.W., Peoples G.E., Kudelka A.P., Murray J.L., Sittisomwong T., Wharton J.T., Kim J.W., Ioannides C.G. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res. 19:1999;2907-2916.
62. Neglia F., Orengo A.M., Cilli M., Meazza R., Tomassetti A., Canevari S., Melani C., Colombo M.P., Ferrini S. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther. 6:1999;349-357.
63. Peoples G.E., Anderson B.W., Lee T.V., Murray J.L., Kudelka A.P., Wharton J.T., Ioannides C.G. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin. Cancer Res. 5:1999;4214-4223.
64. Rodolfo M., Melani C., Zilocchi C., Cappetti B., Luison E., Arioli I., Parenza M., Canevari S., Colombo M.P. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 58:1998;5812-5817.
65. Rodolfo M., Zilocchi C., Cappetti B., Parmiani G., Melani C., Colombo M.P. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. Gene Ther. 6:1999;865-872.
66. Rodolfo M., Zilocchi C., Accornero P., Cappetti B., Arioli I., Colombo M.P. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. J. Immunol. 163:1999;1923-1928.
67. Kershaw M.H., Westwood J.A., Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat. Biotechnol. 20:2002;1221-1227.
68. Lu Y., Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51:2002;153-162.
69. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42:1999;1609-1616.
70. Antony A.C., Utley C., Van Horne K.C., Kolhouse J.F. Isolation and characterization of a folate receptor from human placenta. J. Biol. Chem. 256:1981;9684-9692.
71. Elwood P.C., Kane M.A., Portillo R.M., Kolhouse J.F. The isolation, characterization, and comparison of the membrane-associated and soluble folate-binding proteins from human KB cells. J. Biol. Chem. 261:1986;15416- 15423.
72. Selhub J., Franklin W.A. The folate-binding protein of rat kidney. Purification, properties, and cellular distribution. J. Biol. Chem. 259:1984;6601-6606.
73. Suleiman S.A., Spector R. Purification and characterization of a folate binding protein from porcine choroid plexus. Arch. Biochem. Biophys. 208:1981;87-94.
74. Antony A.C., Utley C.S., Marcell P.D., Kolhouse J.F. Isolation, characterization, and comparison of the solubilized particulate and soluble folate binding proteins from human milk. J. Biol. Chem. 257:1982;10081-10089.
75. Svendsen I.D., Hansen S.I., Holm J., Lyngbye J. Amino acid sequence homology between human and bovine low molecular weight folate binding protein isolated from milk. Carlsberg Res. Commun. 47:1982;371-376.
76. Svendsen I.D., Hansen S.I., Holm J., Lyngbye J. The complete amino acid sequence of the folate binding protein from cow's milk. Carlsberg Res. Commun. 49:1984;123-131.
77. Brigle K.E., Westin E.H., Houghton M.T., Goldman I.D. Characterization of two cDNAs encoding folate-binding proteins from L1210 murine leukemia cells. Increased expression associated with a genomic rearrangement. J. Biol. Chem. 266:1991;17243-17249.
78. Shen F., Wang H., Zheng X., Ratnam M. Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. Biochem. J. 327:1997;759-764.
79. Luhrs C.A., Slomiany B.L. A human membrane-associated folate binding protein is anchored by a glycosyl-phosphatidylinositol tail. J. Biol. Chem. 264:1989;21446-21449.
80. Yan W., Ratnam M. Preferred sites of glycosylphosphatidylinositol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal. Biochemistry. 34:1995;14594-14600.
81. Luhrs C.A., Pitiranggon P., da Costa M., Rothenberg S.P., Slomiany B.L., Brink L., Tous G.I., Stein S. Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation. Proc. Natl. Acad. Sci. USA. 84:1987;6546-6549.
82. Kamen B.A., Wang M.T., Streckfuss A.J., Peryea X., Anderson R.G. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J. Biol. Chem. 263:1988;13602-13609.
83. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA. 88:1991;5572-5576.
84. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell Sci. 106:1993;423-430.
85. Wu M., Fan J., Gunning W., Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J. Membr. Biol. 159:1997;137-147.
86. Wang J., Gunning W., Kelley K.M., Ratnam M. Evidence for segregation of heterologous GPI-anchored proteins into separate lipid rafts within the plasma membrane. J. Membr. Biol. 189:2002;35-43.
87. Wang X., Shen F., Freisheim J.H., Gentry L.E., Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. 44:1992;1898-1901.
88. Brigle K.E., Spinella M.J., Westin E.H., Goldman I.D. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem. Pharmacol. 47:1994;337-345.
89. Maziarz K.M., Monaco H.L., Shen F., Ratnam M. Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta. J. Biol. Chem. 274:1999;11086-11091.
90. Shen F., Zheng X., Wang J., Ratnam M. Identification of amino acid residues that determine the differential ligand specificities of folate receptors alpha and beta. Biochemistry. 36:1997;6157-6163.
91. da Costa M., Sharon M. The synthesis of folate-binding protein in lymphocytes during transformation. Br. J. Haematol. 46:1980;575-579.
92. Hansen S.I., Holm J., Lyngbye J. A high-affinity folate binding protein in human cerebrospinal fluid. Acta Neurol. Scand. 71:1985;133-135.
93. Hansen S.I., Holm J., Hoier-Madsen M. A high-affinity folate binding protein in human urine. Radioligand binding characteristics, immunological properties and molecular size. Biosci. Rep. 9:1989;93-97.
94. Holm J., Hansen S.I., Hoier-Madsen M. A high-affinity folate binding protein in human amniotic fluid. Radioligand binding characteristics, immunological properties and molecular size. Biosci. Rep. 10:1990;79-85.
95. Kamen B.A., Caston J.D. Purification of folate binding factor in normal umbilical cord serum. Proc. Natl. Acad. Sci. USA. 72:1975;4261-4264.
96. 2+-dependent protease in human placenta which cleaves hydrophobic folate-binding proteins to hydrophilic forms. J. Biol. Chem. 264:1989;1911-1914.
97. Elwood P.C., Deutsch J.C., Kolhouse J.F. The conversion of the human membrane-associated folate binding protein (folate receptor) to the soluble folate binding protein by a membrane-associated metalloprotease. J. Biol. Chem. 266:1991;2346-2353.
98. Yang X.Y., Mackins J.Y., Li Q.J., Antony A.C. Isolation and characterization of a folate receptor-directed metalloprotease from human placenta. J. Biol. Chem. 271:1996;11493-11499.
99. Wang J., Shen F., Yan W., Wu M., Ratnam M. Proteolysis of the carboxyl-terminal GPI signal independent of GPI modification as a mechanism for selective protein secretion. Biochemistry. 36:1997;14583-14592.
100. Colman N., Hettiarachchy N., Herbert V. Detection of a milk factor that facilitates folate uptake by intestinal cells. Science. 211:1981;1427-1429.
101. Mason J.B., Selhub J. Folate-binding protein and the absorption of folic acid in the small intestine of the suckling rat. Am. J. Clin. Nutr. 48:1988;620-625.
102. Mantovani L.T., Miotti S., Menard S., Canevari S., Raspagliesi F., Bottini C., Bottero F., Colnaghi M.I. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur. J. Cancer. 30A:1994;363-369.
103. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 73:1994;2432-2443.
104. Miotti S., Canevari S., Menard S., Mezzanzanica D., Porro G., Pupa S.M., Regazzoni M., Tagliabue E., Colnaghi M.I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer. 39:1987;297-303.
105. Stein R., Goldenberg D.M., Mattes M.J. Normal tissue reactivity of four anti-tumor monoclonal antibodies of clinical interest. Int. J. Cancer. 47:1991;163-169.
106. Weitman S.D., Weinberg A.G., Coney L.R., Zurawski V.R., Jennings D.S., Kamen B.A. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 52:1992;6708-6711.
107. Veggian R., Fasolato S., Menard S., Minucci D., Pizzetti P., Regazzoni M., Tagliabue E., Colnaghi M.I. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori. 75:1989;510-513.
108. Buist M.R., Molthoff C.F., Kenemans P., Meijer C.J. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. J. Clin. Pathol. 48:1995;631-636.
109. Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L. Jr., Old L.J., Rettig W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142:1993;557-567.
110. Wu M., Gunning W., Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomarkers Prev. 8:1999;775-782.
111. Chancy C.D., Kekuda R., Huang W., Prasad P.D., Kuhnel J.M., Sirotnak F.M., Roon P., Ganapathy V., Smith S.B. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J. Biol. Chem. 275:2000;20676-20684.
112. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R. Jr., Kamen B.A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52:1992;3396-3401.
113. Hjelle J.T., Christensen E.I., Carone F.A., Selhub J. Cell fractionation and electron microscope studies of kidney folate-binding protein. Am. J. Physiol. 260:1991;C338-C346.
114. Bueno R., Appasani K., Mercer H., Lester S., Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 121:2001;225-233.
115. Campbell I.G., Jones T.A., Foulkes W.D., Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:1991;5329-5338.
116. Evans C.O., Young A.N., Brown M.R., Brat D.J., Parks J.S., Neish A.S., Oyesiku N.M. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J. Clin. Endocrinol. Metab. 86:2001;3097-3107.
117. Weitman S.D., Frazier K.M., Kamen B.A. The folate receptor in central nervous system malignancies of childhood. J. Neurooncol. 21:1994;107-112.
118. Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M., Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer. 74:1997;193-198.
119. Orr R.B., Kreisler A.R., Kamen B.A. Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers. J. Natl. Cancer Inst. 87:1995;299-303.
120. Ross J.F., Wang H., Behm F.G., Mathew P., Wu M., Booth R., Ratnam M. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 85:1999;348-357.
121. Turk M.J., Breur G.J., Widmer W.R., Paulos C.M., Xu L.C., Grote L.A., Low P.S. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 46:2002;1947-1955.
122. Wang H., Ross J.F., Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type gamma/gamma′ Nucleic Acids Res. 26:1998;2132-2142.
123. Ragoussis J., Senger G., Trowsdale J., Campbell I.G. Genomic organization of the human folate receptor genes on chromosome 11q13. Genomics. 14:1992;423-430.
124. Elwood P.C., Nachmanoff K., Saikawa Y., Page S.T., Pacheco P., Roberts S., Chung K.N. The divergent 5′ termini of the alpha human folate receptor (hFR) mRNAs originate from two tissue-specific promoters and alternative splicing: characterization of the alpha hFR gene structure. Biochemistry. 36:1997;1467-1478.
125. Saikawa Y., Price K., Hance K.W., Chen T.Y., Elwood P.C. Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. Biochemistry. 34:1995;9951-9961.
126. Sadasivan E., Cedeno M.M., Rothenberg S.P. Characterization of the gene encoding a folate-binding protein expressed in human placenta. Identification of promoter activity in a G-rich SP1 site linked with the tandemly repeated GGAAG motif for the ets encoded GA-binding protein. J. Biol. Chem. 269:1994;4725-4735.
127. Page S.T., Owen W.C., Price K., Elwood P.C. Expression of the human placental folate receptor transcript is regulated in human tissues. Organization and full nucleotide sequence of the gene. J. Mol. Biol. 229:1993;1175-1183.
128. Roberts S.J., Chung K.N., Nachmanoff K., Elwood P.C. Tissue-specific promoters of the alpha human folate receptor gene yield transcripts with divergent 5′ leader sequences and different translational efficiencies. Biochem. J. 326:1997;439-447.
129. Coney L.R., Tomassetti A., Carayannopoulos L., Frasca V., Kamen B.A., Colnaghi M.I., Zurawski V.R. Jr. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 51:1991;6125-6132.
130. Tomassetti A., Mangiarotti F., Mazzi M., Sforzini S., Miotti S., Galmozzi E., Elwood P.C., Canevari S. The variant hepatocyte nuclear factor 1 activates the P1 promoter of the human alpha-folate receptor gene in ovarian carcinoma. Cancer Res. 63:2003;696-704.
131. Hao H., Qi H., Ratnam M. Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites. Blood. 101:2003;4551-4560.
132. Kelley K.M., Wang H., Ratnam M. Dual regulation of ets-activated gene expression by SP1. Gene. 307:2003;87-97.
133. Galmozzi E., Tomassetti A., Sforzini S., Mangiarotti F., Mazzi M., Nachmanoff K., Elwood P.C., Canevari S. Exon 3 of the alpha folate receptor gene contains a 5′ splice site which confers enhanced ovarian carcinoma specific expression. FEBS Lett. 502:2001;31-34.
134. Zheng X., Kelley K., Elnakat H., Yan W., Dorn T., Ratnam M. mRNA instability in the nucleus due to a novel open reading frame element is a major determinant of the narrow tissue specificity of folate receptor alpha. Mol. Cell Biol. 23:2003;2202-2212.
135. Kane M.A., Elwood P.C., Portillo R.M., Antony A.C., Najfeld V., Finley A., Waxman S., Kolhouse J.F. Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells. J. Clin. Invest. 81:1988;1398-1406.
136. McHugh M., Cheng Y.C. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J. Biol. Chem. 254:1979;11312-11318.
137. Sun X.L., Antony A.C. Evidence that a specific interaction between an 18-base cis-element in the 5′-untranslated region of human folate receptor-alpha mRNA and a 46-kDa cytosolic trans-factor is critical for translation. J. Biol. Chem. 271:1996;25539-25547.
138. Xiao X., Tang Y.S., Mackins J.Y., Sun X.L., Jayaram H.N., Hansen D.K., Antony A.C. Isolation and characterization of a folate receptor mRNA-binding trans-factor from human placenta. Evidence favoring identity with heterogeneous nuclear ribonucleoprotein E1. J. Biol. Chem. 276:2001;41510-41517.
139. Hsueh C.T., Dolnick B.J. Altered folate-binding protein mRNA stability in KB cells grown in folate-deficient medium. Biochem. Pharmacol. 45:1993;2537-2545.
140. Zhu W.Y., Alliegro M.A., Melera P.W. The rate of folate receptor alpha (FR alpha) synthesis in folate depleted CHL cells is regulated by a translational mechanism sensitive to media folate levels, while stable overexpression of its mRNA is mediated by gene amplification and an increase in transcript half-life. J. Cell Biochem. 81:2001;205-219.
141. Wang H., Zheng X., Behm F.G., Ratnam M. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood. 96:2000;3529-3536.
142. Bolton J.A., Wood S.A., Kennedy D., Don R.H., Mattick J.S. Retinoic acid-dependent upregulation of mouse folate receptor-alpha expression in embryonic stem cells, and conservation of alternative splicing patterns. Gene. 230:1999;215-224.
143. Tallman M.S. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia. 12:(Suppl. 1):1998;S37-S40.
144. Rochman H., Selhub J., Karrison T. Folate binding protein and the estrogen receptor in breast cancer. Cancer Detect. Prev. 8:1985;71-75.
145. Kelley K.M., Rowan B.G., Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res. 63:2003;2820-2828.